Related Experiment Video
Updated: Jul 12, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
DUSP1 Signaling Pathway Regulates Cytarabine Sensitivity in Acute Myeloid Leukemia
Huali Sun1, Yanling Ren2, Xinping Zhou2
1Department of Radiotherapy, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, China.
Abstract:
Objectives: Dual specificity phosphatase 1 (DUSP1) is high-expressed in various cancers and plays an important role in the cellular response to agents that damage DNA. We aimed to investigate the expressions and mechanisms of DUSP1 signaling pathway regulating cytarabine (Ara-C) resistance in acute myeloid leukemia (AML). Methods: Immunohistochemistry was performed on bone marrow biopsy specimens from AML and controls to explore the expression of DUSP1. Western blot and Q-PCR were used to detect the protein and mRNA expression levels. MTT assay was used to detect the proliferation of cells. Cell apoptosis was detected by flow cytometry. The immune protein-protein interaction (PPI) network of DUSP1 was analyzed in the platform of Pathway Commons, and immune infiltration analysis was used to study the immune microenvironment of AML. Results: We found that the expression levels of DUSP1 in AML patients exceeded that in controls. Survival analysis in public datasets showed that AML patients with higher levels of DUSP1 had poor clinical outcomes. Further public data analysis indicated that DUSP1 was overexpressed in NRAS mutated AML. DUSP1 knockdown by siRNA could sensitize AML cells to Ara-C treatments. The phosphorylation level of mitogen-activated protein kinase (MAPK) pathway was significantly elevated in DUSP1 down-regulated NRAS G13D mutated AML cells. The PPI analysis showed DUSP1 correlated with immune gene CREB1 and CXCL8 in NRAS mutated AML. We also revealed a correlation between tumor-infiltrating immune cells in RAS mutated AML microenvironment. Conclusion: Our findings suggest that DUSP1 signaling pathways may regulate Ara-C sensitivity in AML.
Insights
Dual specificity phosphatase 1 (DUSP1) is highly expressed in acute myeloid leukemia (AML) and linked to poor outcomes. Inhibiting DUSP1 may increase sensitivity to cytarabine (Ara-C) treatment in AML.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Dual specificity phosphatase 1 (DUSP1) is upregulated in various cancers.
- DUSP1 plays a key role in cellular responses to DNA-damaging agents.
- Understanding DUSP1's role in acute myeloid leukemia (AML) is crucial for treatment strategies.
Purpose of the Study:
- To investigate DUSP1 expression and its regulatory mechanisms in cytarabine (Ara-C) resistance in AML.
- To explore the correlation between DUSP1, the MAPK pathway, and immune microenvironment in AML.
Main Methods:
- Immunohistochemistry and Western blot for DUSP1 expression analysis.
- Quantitative PCR (Q-PCR) for mRNA levels.
- MTT assays and flow cytometry for cell proliferation and apoptosis.
- Protein-protein interaction (PPI) network analysis and immune infiltration analysis.
Main Results:
- DUSP1 expression is elevated in AML patients compared to controls.
- High DUSP1 levels correlate with poor clinical outcomes and are overexpressed in NRAS-mutated AML.
- DUSP1 knockdown sensitizes AML cells to Ara-C, increasing MAPK pathway phosphorylation.
- DUSP1 correlates with immune genes CREB1 and CXCL8, and tumor-infiltrating immune cells in RAS-mutated AML.
Conclusions:
- DUSP1 signaling pathways are implicated in regulating Ara-C sensitivity in AML.
- DUSP1 may serve as a potential therapeutic target for overcoming Ara-C resistance in AML.
Related Concept Videos
Inhibition of Cdk Activity
Abnormal Proliferation
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Treatment Resistant Cancers
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Targeted Cancer Therapies
There are several types of targeted therapies against...

